Group 1 - The core viewpoint of the article is that China Biologic Products (01177) has completed the enrollment of subjects for the Phase III clinical trials of two drugs, TQB2102 and LM302 [1] - LM302 is noted as the world's first CLDN18.2 antibody drug complex to complete subject enrollment in Phase III registration clinical trials, potentially providing new treatment options for patients [1] - Bank of America Securities has set a target price of HKD 8.6 and reiterated a "Buy" rating for the company [1]

Core Viewpoint - Bank of America Securities reports that China Biologic Products (01177) has completed patient enrollment for Phase III clinical trials of two drugs, TQB2102 and LM302, with LM302 being the first CLDN18.2 antibody drug conjugate to complete such enrollment globally, potentially offering new treatment options for patients [1] Group 1 - China Biologic Products has completed patient enrollment for Phase III clinical trials of TQB2102 and LM302 [1] - LM302 is noted as the world's first CLDN18.2 antibody drug conjugate to finish Phase III registration clinical trial enrollment [1] - Bank of America Securities sets a target price of HKD 8.6 and maintains a "Buy" rating for the stock [1]

Core Viewpoint - Bank of America Securities reports that two drugs from a Chinese biopharmaceutical company, TQB2102 and LM302, have recently completed patient enrollment for Phase III clinical trials, with LM302 being the first CLDN18.2 antibody-drug conjugate to complete this phase globally, potentially offering new treatment options for patients [1] Group 1 - The two drugs, TQB2102 and LM302, have completed patient enrollment for Phase III clinical trials [1] - LM302 is noted as the world's first CLDN18.2 antibody-drug conjugate to complete Phase III registration clinical trial enrollment [1] - The target price for the company is set at HKD 8.6, with a reiterated "Buy" rating [1]